Get the Stockscreener App
9.22
1.39%
-0.13
Immatics N V stock is traded at $9.22, with a volume of 134.80K.
It is down -1.39% in the last 24 hours and down -15.10% over the past month.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
See More
Previous Close:
$9.35
Open:
$9.31
24h Volume:
134.80K
Relative Volume:
0.28
Market Cap:
$1.10B
Revenue:
$58.49M
Net Income/Loss:
$-105.04M
P/E Ratio:
-7.776
EPS:
-1.1857
Net Cash Flow:
$-13.78M
1W Performance:
-1.50%
1M Performance:
-15.10%
6M Performance:
-14.39%
1Y Performance:
-4.06%
1-Day Range:
$9.06
$9.31
1-Week Range:
$8.962
$9.485
52-Week Range:
$7.98
$13.77
Immatics N V Stock (IMTX) Company Profile
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Nov-20-20 | Initiated | BofA Securities | Buy |
| Sep-22-20 | Initiated | Goldman | Buy |
| Jul-27-20 | Initiated | SVB Leerink | Outperform |
| Jul-24-20 | Initiated | Jefferies | Buy |
View All
Immatics N V Stock (IMTX) Latest News
Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
abrdn plc Invests $2.66 Million in Immatics (NASDAQ:IMTX) - MarketBeat
Objective long/short (IMTX) Report - Stock Traders Daily
Short Interest in Immatics (NASDAQ:IMTX) Expands By 5.3% - MarketBeat
Shareholders in Immatics (NASDAQ:IMTX) have lost 35%, as stock drops 6.3% this past week - Simply Wall St
Immatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50% - Yahoo Finance
Perceptive Advisors LLC Reduces Stake in Immatics NV - Yahoo Finance
Immatics N.V. Announces Major Share Offering - TipRanks
Market Update: Immatics N.V (IMTX) Sees Negative Movement, Closing at 9.30 - The Dwinnex
Immatics (NASDAQ:IMTX) Short Interest Update - MarketBeat
It makes sense and dollars to buy Immatics N.V (IMTX) stock - SETE News
206,920 Shares in Immatics (NASDAQ:IMTX) Bought by Cubist Systematic Strategies LLC - MarketBeat
Immatics: A Promising TCR Pipeline (NASDAQ:IMTX) - Seeking Alpha
Upstream catches aftermarket updraft, as Camp4 IPO gets muted reception - BioCentury
Immatics (NASDAQ:IMTX) Sees Large Volume IncreaseWhat's Next? - MarketBeat
A closer look at IMTX’s price-to-free cash flow ratio - US Post News
Ratio Analysis: Unpacking Immatics N.V (IMTX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Immatics Advances IMA203 to Phase 3 Trial in Melanoma - Yahoo Finance
Immatics Announces Pricing of $150 Million Public Offering - StockTitan
Immatics Off To Phase III With IMA203 After Positive Melanoma Results - Scrip
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday? - AOL
IMTX: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Immatics Announces Proposed $150 Million Public Offering - GlobeNewswire
Immatics (NASDAQ:IMTX) Shares Gap DownHere's What Happened - MarketBeat
Form 424B2 Immatics N.V. - StreetInsider.com
Immatics provides update on Phase 1b trial of ACTengine in melanoma - TipRanks
Form 6-K Immatics N.V. For: Oct 10 - StreetInsider.com
Immatics Announces Updated Phase 1b Clinical Data on - GlobeNewswire
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial - StockTitan
Immatics N.V. (IMTX) Receives Buy Rating from Analysts - Insider Monkey
Immatics (NASDAQ:IMTX) Shares Gap UpHere's Why - MarketBeat
Immatics (NASDAQ:IMTX) Earns Overweight Rating from Analysts at Piper Sandler - MarketBeat
Piper Sandler sees blockbuster potential in Immatics stock due to PRAME portfolio - Investing.com UK
Immatics Announces Upcoming Oral and Poster Presentations - GlobeNewswire
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 - StockTitan
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual… - Informazione.it
Immatics (NASDAQ:IMTX) Shares Down 4.4% - MarketBeat
Quarry LP Buys Shares of 8,500 Immatics (NASDAQ:IMTX) - Defense World
How To Trade (IMTX) - Stock Traders Daily
Immatics (NASDAQ:IMTX) is Perceptive Advisors LLC's 10th Largest Position - MarketBeat
Forefront Analytics LLC Invests $139,000 in Immatics (NASDAQ:IMTX) - Defense World
Frazier Life Sciences Management L.P. Takes $13.39 Million Position in Immatics (NASDAQ:IMTX) - MarketBeat
XTX Topco Ltd Takes $321,000 Position in Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) Shares Sold by Affinity Asset Advisors LLC - MarketBeat
Affinity Asset Advisors LLC Sells 50,000 Shares of Immatics (NASDAQ:IMTX) - Defense World
HighVista Strategies LLC Makes New Investment in Immatics (NASDAQ:IMTX) - MarketBeat
HighVista Strategies LLC Acquires New Shares in Immatics (NASDAQ:IMTX) - Defense World
Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues - Simply Wall St
KKR and Impilo complete acquisition of Immedica Pharma - Marketscreener.com
(IMTX) On The My Stocks Page - Stock Traders Daily
Leerink Partnrs Comments on Immatics' FY2024 Earnings (NASDAQ:IMTX) - MarketBeat
Immatics N V Stock (IMTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):